Tharun is a Chartered Financial Analyst from the CFA Institute, U.S. A graduate from Loyola College, Chennai, he started his career in Goldman Sachs at their Bangalore office. Prior to his current role at Proactive Investors, he worked as an equity analyst at a global research and analytics company in Mumbai, assisting institutional clients across Asia.
The TAVR heart valve device utilises the company’s ADAPT® technology.
MPS or mucopolysaccharidoses is an orphan indication with market exclusivity and high profit margins.
Recently published study findings show Cellmid’s midkine antibodies prevented heart muscle damage and preserved function.
Leo Lee has extensive experience in leading pharmaceutical companies in Japan having been the former president of Japan for both Merck and Allergan.
The company said planned investment in the period and a softening of growth in China has had a short-term impact on profit growth.
The company’s lead candidate RECCE® 327 has been developed for the treatment of blood infections and sepsis derived from E. coli and S. aureus bacteria.
Following the successful licencing of its animal health product to Zoetis Inc, Anatara is now focused on building a pipeline of human gastrointestinal health products.
The collaboration agreement is an important advancement for Invitrocue to expand into multiple subtypes of the world’s leading cancer for women.